Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TAK-071 · 1 trial · 2 indications
Stride time (or gait) is defined as the time elapsed between the first contact of two consecutive footsteps of the same foot and is expressed in seconds. The standard deviation (SD) of the stride time, recorded for each foot during the 2-minutes, is averaged to obtain stride time (gait) variability. The 2-minute walk was performed with and without simultaneous performance of serial 3 subtraction, which adds a cognitive load to the task. Data are reported with and without cognitive load.
| Arm | Type | Description |
|---|---|---|
| Placebo + TAK-071 (PD Participants) | EXPERIMENTAL | TAK-071 placebo-matching tablets, orally, once daily for up to first 6 weeks in Period 1, followed by ≥3 weeks washout period, followed by TAK-071 tablets, orally, once daily for up to next 6 weeks in Period 2. |
| TAK-071 + Placebo (PD Participants) | EXPERIMENTAL | TAK-071 tablets, orally, once daily for up to first 6 weeks in Period 1, followed by ≥3 weeks washout period, followed by TAK-071 placebo-matching tablets, orally, once daily for up to next 6 weeks in Period 2. |
| Sentinel Cohort: Placebo (Healthy Participants) | EXPERIMENTAL | A single dose of TAK-071 placebo-matching mg, tablet, orally, on Day 1. |
| Sentinel Cohort: TAK-071 7.5 mg (Healthy Participants) | EXPERIMENTAL | A single dose of TAK-071 ≤ 7.5 milligrams (mg), tablet, orally, on Day 1. |
| Name | Type | Description |
|---|---|---|
| TAK-071 | DRUG | TAK-071 tablet. |
| Placebo | DRUG | TAK-071 placebo-matching tablet. |
Key Inclusion Criteria: 1. Is an outpatient of any sex aged between 40 and ≤ 85 years, inclusive, at the time of consent. 2. Has a diagnosis of PD according to Movement Disorders Society (MDS) clinical diagnostic criteria for PD. Participants with DLB (i.e., dementia diagnosed before onset of motor...
Top 15 of 23 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Supernus Pharmaceuticals, Inc. | SUPN | 2 | PHASE3 | Onapgo (SPN-830) |
| Prothena Corp. Plc | PRTA | 3 | PHASE3 | Prasinezumab |
| Denali Therapeutics Inc. | DNLI | 1 | PHASE2 | BIIB122 |
| Bayer | BAYRY | 4 | PHASE3 | bemdaneprocel, AB-1005 |
| Biohaven Ltd. | BHVN | 1 | PHASE2 | BHV-8000 |
| AC Immune SA | ACIU | 2 | PHASE2 | ACI-7104.056 |
| Eli Lilly and Company | LLY | 4 | PHASE1 | LY3884961, LY4006896, LY3962681 |
| Gain Therapeutics, Inc. | GANX | 2 | PHASE2 | GT-02287 |
| Annovis Bio Inc | ANVS | 1 | PHASE2 | Buntanetap |
| Regeneron Pharmaceuticals, Inc. | REGN | 2 | PHASE1 | ALN-SNCA |
| MeiraGTx Holdings Plc | MGTX | 1 | PHASE1 | AAV-GAD |
| Serina Therapeutics, Inc. | SER | 1 | PHASE1 | SER-252 |
| Ardelyx, Inc. | ARDX | 1 | PHASE2 | Tenapanor |
| Hoffmann-La Roche | RHHBY | 1 | PHASE1 | RO7568282 |
| Merck & Co., Inc. | MRK | 1 | EARLY_PHASE1 | MK-0947 |
TAK-071 is an investigational small molecule developed by Takeda Pharmaceutical Company Limited for Parkinson disease. It is a positive allosteric modulator of CHRM1, also known as the M1 muscarinic acetylcholine receptor. It has been studied in a Phase 2 clinical trial and is not approved for any indication.
TAK-071 is being developed as a potential treatment for Parkinson disease. It is designed to modulate the CHRM1 receptor, a muscarinic acetylcholine receptor subtype, and has been evaluated in a Phase 2 clinical trial that enrolled 64 participants with Parkinson disease and healthy participants.
TAK-071 targets CHRM1, the M1 muscarinic acetylcholine receptor. It acts as a positive allosteric modulator, meaning it enhances the receptor's response to acetylcholine rather than directly activating it. This mechanism is being explored in Parkinson disease.
TAK-071 is being developed by Takeda Pharmaceutical Company Limited, which trades under the ticker TAK. Takeda is the sponsor of the clinical program evaluating TAK-071 in Parkinson disease.
TAK-071 is in Phase 2 clinical development. A Phase 2 trial in Parkinson disease has been completed. TAK-071 is investigational and has not been approved by the FDA or any regulatory agency for any indication.
TAK-071 has been studied in a completed Phase 2 trial, NCT04334317, titled A Study of TAK-071 in People With Parkinson Disease. The trial enrolled 64 participants, was randomized, double-blind, and controlled, and was conducted in the United States.